

ROCHELLE SUN

rochellesun@g.harvard.edu

1737 Cambridge St., CGIS Knafel
Cambridge, MA 02138

EDUCATION

2022- Present **Harvard University**

PhD student, Department of Government

Affiliations: Center for American Politics, Institute for Quantitative Social Science,
Weatherhead Center for International Affairs

2015- 2019 **University of Rochester**

BA, Political Science and Health Policy (highest distinction)

ACADEMIC PUBLICATIONS

- 2023 Khera, N; Edwards, ML; Song, Y; **Sun, R**; Manghani, R; Shin, H; Simantov, R; Signorovitch, J; Sivaraman, S; Gergis, U. Projected Impact of Omidubicel on Racial and Ethnic Disparities in Allogeneic Hematopoietic Cell Transplant Outcomes in Hematologic Malignancies. *Under review Transplantation and Cellular Therapy*.
- 2023 Driessen, M; Heinze, A; Afridi, S; Totev, TI; Krasenbaum, LJ; Terasawa, E; Akcicek, H; Hipp, J; Dhiraj, D; **Sun, R**; Yim, E; Yilma, B. Real-world Clinical Effectiveness Outcomes and Reductions in Migraine-related Medication and Health Care Resource Utilization for Patients Initiating Fremanezumab in Germany and the United Kingdom. *Under review at European Journal of Neurology*.
- 2022 Kim, N; Wang, J; Burudpakdee, C; Song, Y; Ramasamy, A; Xie, Y; **Sun, R**; Kumar, N; Wu, EQ; Sullivan, SD. [Cost-effectiveness Analysis of Semaglutide 2.4 mg for the Treatment of Adult Patients with Overweight and Obesity in the United States](#). *Journal of Managed Care and Pharmacy*. 2022 Jul; 28(7):740-752. *Most viewed publication of 2022, Journal of Managed Care and Pharmacy*
- 2022 Driessen, MT; Cohen, JM; Patterson-Lomba, O; Thompson, SF; Seminerio, M; Carr, K; Totev, TI; **Sun, R**; Yim, E; Mu, F; Ayyagari, R. [Real-World Effectiveness Of Fremanezumab In Migraine Patients Initiating Treatment in the United States: Results from a Retrospective Chart Study](#). *Journal of Headache and Pain*. 2022 Apr; 23(1):47.
- 2022 Driessen, MT; Cohen, JM; Thompson, SF; Patterson-Lomba, O; Seminerio, MJ; Carr, K; Totev, TI; **Sun, R**; Yim, E; Mu, F; Ayyagari, R. [Real-world Effectiveness After Initiating Fremanezumab Treatment in US Patients With Episodic and Chronic Migraine or Difficult-to-Treat Migraine](#). *Journal of Headache and Pain*. 2022 May; 23(1):56.
- 2022 Conaghan, P; Cohen, S; Burmester, G; Mysler, E; Nash, P; Tanaka, Y; Rigby, W; Patel, J; Shaw, T; Betts, KA; Patel, P; Liu, J; **Sun, R**; Fleischmann, R. Benefit-Risk Analysis of [Upadacitinib compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis](#). *Rheumatology and Therapy*. 2022 Feb; 9(1):191-206.

- 2021 Pierre, S; Bocharova, I; Nguyen, C; Homeus, F; Julmiste, G; Macius, Y; Rouzier, V; Severe, P; Deschamps, MM; Guiteau, C; Bellot, C; Wu, J; Rivera, V; **Sun, R**; Pape, JW; Liautaud, BL, Koenig, SP. [Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti](#). *Open Forum Infect Diseases*. 2021 Nov; 8(12):559.

CONFERENCE PRESENTATIONS

- 2022 Maintaining patient care in the context of major and prolonged socio-political turmoil in Haiti through community care centers for ART distribution and viral load testing. Poster presented at *AIDS 2022, the 24th International AIDS Conference*.
- 2022 Real-world Reductions in Health Care Resource Utilization for Patients with Migraine Initiating Fremanezumab in Germany. Poster presented at *European Academy of Neurology Annual Meeting*.
- 2022 Projected impact of omidubicel on racial and ethnic disparities in allogeneic hematopoietic cell transplant access and outcomes for patients with hematologic malignancies in the US. Poster presented at *Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings*.
- 2021 Real-world reductions in migraine and headache days after initiating fremanezumab for us patients with migraine and prior use of another monoclonal antibody targeting the CGRP pathway. Poster presented at *63rd Annual Scientific Meeting of the American Headache Society*.
- 2021 Fremanezumab treatment results in real-world reductions in monthly migraine and headache days in patients having different numbers of prior migraine preventive treatment failures in this us study. Poster presented at *Academy of Managed Care Pharmacy*.

FIELD RESEARCH

- 2023 Dakar, Senegal: *Medical Humanitarian Aid Delivery in Conflict Settings*

PROFESSIONAL EXPERIENCE

- 2019 - 2022 **Analysis Group, Inc.**
Senior Analyst - Health Economics and Outcomes Research (HEOR)
 Case experience: cost-effectiveness modeling, economic modeling, indirect treatment comparisons (Bayesian network meta-analyses, matching-adjusted indirect comparisons), systematic literature reviews, global pharmaceutical regulatory submissions; physician chart reviews, patient survey studies, data visualization and presentation.
- 2018 **Monroe County Crime Analysis Center (MCAC)**
Research Intern
- 2018 **Center for Strategic and International Studies (CSIS)**
Research Intern
- 2018 **European Parliament**
Legislative Intern

OTHER AFFILIATIONS

2020 - Present **Alliance for International Medical Action (ALIMA)**
Associate Board Member

2020 - Present **Les Centres GHESKIO**
Volunteer Research Associate

SELECTED GRANTS AND AWARDS

2023 Pre-Dissertation Research Grant, Harvard Weatherhead Center for International Affairs

2023 Women and Politics Research Grant, Harvard Department of Government

2023 Best First-time Graduate Student Poster Presenter, Harvard Department of Government

2019 Helen S. Jones Award, University of Rochester Department of Political Science

2019 Phi Beta Kappa, University of Rochester

SKILLS, LANGUAGES, INTERESTS

Research Skills: Data analysis (*R, Excel, Python, Stata, SAS*), Programming (*Python, VBA, HTML, CSS*)

Languages: Chinese - Mandarin (*Intermediate*), French (*Beginner*)

Interests: Houseplants, experimental cooking, spicy foods, dance (lyrical, hip hop, jazz)